Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2001

01-12-2002 | Paper Report

Gene expression signatures may predict clinical outcome

Author: Valerie Speirs

Published in: Breast Cancer Research | Issue 1/2001

Login to get access

Excerpt

Traditional pathological classification of breast tumours is based on a panel of established markers, especially hormone receptor status, axillary lymph node status and histological grade. Unfortunately these fail to accurately predict clinical outcome in some patients. As a result, many patients go on to receive unnecessary adjuvant therapy. The aim of this work was to use gene expression signatures to predict clinical outcome in a cohort of breast tumours. …
Literature
1.
van't Veer LJ, Dai H, van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van Der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536.CrossRef
Metadata
Title
Gene expression signatures may predict clinical outcome
Author
Valerie Speirs
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2002-75350

Other articles of this Issue 1/2001

Breast Cancer Research 1/2001 Go to the issue

Review

The role of bisphosphonates in breast cancer: Development of bisphosphonates

Commentary

Mammographic breast density as a biomarker of effects of isoflavones on the female breast

Paper Report

Quality control of immunohistochemical assay of HER-2/neu expression

Paper Report

What centrosomes can teach us about tumor progression

Review

The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer

Commentary

E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits